Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMingkwan Na Takuathungen_US
dc.contributor.authorWannachai Sakuludomkanen_US
dc.contributor.authorRapheephorn Khatsrien_US
dc.contributor.authorNahathai Dukaewen_US
dc.contributor.authorNapatsorn Kraivisitkulen_US
dc.contributor.authorBalqis Ahmadmusaen_US
dc.contributor.authorChollada Mahakkanukrauhen_US
dc.contributor.authorKachathip Wangthaweesapen_US
dc.contributor.authorJirakit Oninen_US
dc.contributor.authorSalin Srichaien_US
dc.contributor.authorNida Buawangpongen_US
dc.contributor.authorNut Koonrungsesomboonen_US
dc.description.abstractBackground: Although angiotensin-converting enzyme (ACE) inhibitors are among the most-prescribed medications in the world, the extent to which they increase the risk of adverse effects remains uncertain. This study aimed to systematically determine the adverse effects of ACE inhibitors versus placebo across a wide range of therapeutic settings. Methods: Systematic searches were conducted on PubMed, Web of Science, and Cochrane Library databases. Randomized controlled trials (RCTs) comparing an ACE inhibitor to a placebo were retrieved. The relative risk (RR) and its 95% confidence interval (95% CI) were utilized as a summary effect measure. A random-effects model was used to calculate pooled-effect estimates. Results: A total of 378 RCTs fulfilled the eligibility criteria, with 257 RCTs included in the meta-analysis. Compared with a placebo, ACE inhibitors were associated with an significantly increased risk of dry cough (RR = 2.66, 95% CI = 2.20 to 3.20, p < 0.001), hypotension (RR = 1.98, 95% CI = 1.66 to 2.35, p < 0.001), dizziness (RR = 1.46, 95% CI = 1.26 to 1.70, p < 0.001), and hyperkalemia (RR = 1.24, 95% CI = 1.01 to 1.52, p = 0.037). The risk difference was quantified to be 0.037, 0.030, 0.017, and 0.009, respectively. Conclusions: We quantified the relative risk of numerous adverse events associated with the use of ACE inhibitors in a variety of demographics. This information can help healthcare providers be fully informed about any potential adverse consequences and make appropriate suggestions for their patients requiring ACE inhibitor therapy.en_US
dc.subjectEnvironmental Scienceen_US
dc.titleAdverse Effects of Angiotensin-Converting Enzyme Inhibitors in Humans: A Systematic Review and Meta-Analysis of 378 Randomized Controlled Trialsen_US
article.title.sourcetitleInternational Journal of Environmental Research and Public Healthen_US
article.volume19en_US of Medicine, Chiang Mai Universityen_US Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.